MarketCapExport financials
Bolt Biotherapeutics (BOLT)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Bolt Biotherapeutics Income Statement 2025-2011 | BOLT
Brief overview of revenue and earnings at Bolt Biotherapeutics
The figures are compared over a five-year interval. Revenue at Bolt Biotherapeutics moved from $231 thousand in 2020 to $7.7 million in 2025. The five-year change reached +3231.2%, while CAGR stood at 101.6%. Revenue growth reflects a pronounced phase of business expansion.
At the gross-profit level, the result moved from 231 thousand dollars to −5.8 million dollars, a change of −2632%. At the margin level, the figure shifted from 100% to −76%. Weakening gross profitability reduces the quality of the top-line trend.
EBITDA changed from −48.6 million dollars to −34.8 million dollars (+28.3%). EBITDA underperformed the top-line trend. EBITDA margin was −21026.4% at the start and −452.5% at the end. The increased EBITDA share is a positive sign.
The net financial result changed from $0 to −$33.4 million. The final result remained comparatively stable.
Conclusion
The indicators point to a weaker financial profile. The financial profile benefits from an improving EBITDA margin and a larger revenue base. The most visible risks are a low gross margin, weaker gross profitability and a narrow EBITDA buffer. Further direction will depend on top-line growth, operating profitability, and net income.
Annual Income Statement Bolt Biotherapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
11.4 M | 29.2 M | 43.9 M | 50.8 M | 127 M | - | - | - | - | - | - | - | - | - | - |
Shares |
1.87 M | 1.91 M | 37.8 M | 37.4 M | 33.2 M | - | - | - | - | - | - | - | - | - | - |
Historical Prices |
6.12 | 15.3 | 1.16 | 1.36 | 3.84 | - | - | - | - | - | - | - | - | - | - |
Net Income |
-33.4 M | -63.1 M | -69.2 M | -88.1 M | -98.6 M | - | -30.5 M | -11.6 M | - | - | - | - | - | - | - |
Revenue |
7.7 M | 7.69 M | 7.88 M | 5.73 M | 1.26 M | 231 K | 215 K | - | - | - | - | - | - | - | - |
Cost of Revenue |
13.5 M | 23.9 M | 29.5 M | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | 231 K | - | - | - | - | - | - | - | - | - |
Operating Income |
-36.1 M | -73 M | -76.2 M | -90.3 M | -92.8 M | -49.2 M | - | - | - | - | - | - | - | - | - |
EBITDA |
-34.8 M | -71.3 M | -74.3 M | -88.7 M | -91.6 M | -48.6 M | -30.6 M | -11.3 M | - | - | - | - | - | - | - |
Operating Expenses |
43.8 M | 80.7 M | 84.1 M | 96 M | 94 M | 49.4 M | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
13.8 M | 18.5 M | 22.5 M | 22.9 M | 18.4 M | 9.06 M | 5.18 M | 2.21 M | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Bolt Biotherapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
1.92 M | 1.68 M | - | 1.92 M | 1.92 M | 38.3 M | 1.92 M | 1.91 M | 1.91 M | 38.1 M | 38.1 M | 37.9 M | 37.8 M | 37.7 M | 37.8 M | 37.5 M | 37.3 M | 37.1 M | 37.4 M | 37.2 M | 36.6 M | 21.5 M | 2.13 M | 1.98 M | 1.94 M | 1.93 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-8.56 M | -7.24 M | - | -7.14 M | -8.56 M | -11 M | - | -15.2 M | -21.2 M | -10.8 M | - | -16.3 M | -18.1 M | -17 M | - | -21.8 M | -22.7 M | -23.7 M | - | -23.4 M | -23.6 M | -24.5 M | - | -10 M | -11.1 M | -8.63 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
1.8 M | 26 K | - | 2.17 M | 1.8 M | 1.22 M | - | 1.14 M | 1.28 M | 5.27 M | - | 2.53 M | 1.43 M | 1.83 M | - | 2.11 M | 1.39 M | 813 K | - | 752 K | - | - | - | 231 K | 67 K | 164 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
3.98 M | 2.21 M | - | 2.9 M | 3.98 M | 4.69 M | - | 4.93 M | 6.56 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-9.21 M | -7.6 M | - | -7.7 M | -9.21 M | -12.1 M | - | -16.4 M | -22.6 M | -17.1 M | - | -18.2 M | -19.8 M | -18.4 M | - | -22.3 M | -23.1 M | -23.9 M | - | -23.5 M | -23.8 M | -18.4 M | - | -12.4 M | -11.1 M | -8.74 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-8.91 M | -7.4 M | - | -7.4 M | -8.91 M | -11.7 M | - | -15.9 M | -22.2 M | -16.6 M | - | -17.7 M | -19.4 M | -17.9 M | - | -21.9 M | -22.7 M | -23.5 M | - | -22.7 M | -23.2 M | -18.2 M | - | -12 M | -10.9 M | -8.64 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
11 M | 7.63 M | - | 9.87 M | 11 M | 13.3 M | - | 17.6 M | 23.9 M | 22.4 M | - | 20.7 M | 21.3 M | 20.2 M | - | 24.5 M | 24.5 M | 24.7 M | - | 24.3 M | 23.8 M | 18.4 M | - | 12.4 M | 11.2 M | 8.91 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
3.52 M | 2.8 M | - | 3.34 M | 3.52 M | 3.82 M | - | 3.8 M | 4.87 M | 5.84 M | - | 5.76 M | 5.62 M | 5.62 M | - | 5.48 M | 5.53 M | 6.3 M | - | 4.94 M | 4.05 M | 4.3 M | - | 2.86 M | 2.01 M | 2.12 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Bolt Biotherapeutics (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.